Clinical Trial Update: Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating re-irradiation with fractionated stereotactic radiosurgery plus cetuximab in patients with recurrent squamous cell carcinoma of the hea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: David A. Clump, MD, PhD | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2022-02-14